



ORIGINAL ARTICLE

Validation of transcutaneous bilirubin nomogram for identifying neonatal hyperbilirubinemia in healthy Chinese term and late-preterm infants: a multicenter study[☆]

Zhangbin Yu^a, Shuping Han^a, Jinxia Wu^b, Mingxia Li^c, Huaiyan Wang^d,
Jimei Wang^e, Jiebo Liu^f, Xinnian Pan^g, Jie Yang^h, Chao Chen^{i,*}

^a Department of Pediatrics, Nanjing Maternity and Child Health Care Hospital of Nanjing Medical University, Nanjing, China

^b Department of Neonatology, Inner Mongolia Maternal and Child Health Care Hospital, Huhehot, China

^c Department of Neonatology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China

^d Department of Neonatology, Changzhou Maternal and Child Health Care Hospital, Changzhou, China

^e Department of Neonatology, Gynecology and Obstetrics Hospital, Fudan University, Shanghai, China

^f Department of Pediatrics, The Fifth People's Hospital of Shenzhen, Shenzhen, China

^g Department of Neonatology, Guangxi Maternal and Child Health Hospital, Nanning, China

^h Department of Neonatology, Guangdong Maternal and Children's Hospital, Guangzhou Medical College, Guangzhou, China

ⁱ Department of Neonatology, Children's Hospital of Fudan University, Shanghai, China

Received 18 July 2013; accepted 20 August 2013

Available online 5 February 2014

KEYWORDS

Hyperbilirubinemia;
Jaundice;
Neonatal;
Bilirubin;
Newborn

Abstract

Objective: to prospectively validate a previously constructed transcutaneous bilirubin (TcB) nomogram for identifying severe hyperbilirubinemia in healthy Chinese term and late-preterm infants.

Methods: this was a multicenter study that included 9,174 healthy term and late-preterm infants in eight hospitals of China. TcB measurements were performed using a JM-103 bilirubinometer. TcB values were plotted on a previously developed TcB nomogram, to identify the predictive ability for subsequent significant hyperbilirubinemia.

Results: in the present study, 972 neonates (10.6%) developed significant hyperbilirubinemia. The 40th percentile of the nomogram could identify all neonates who were at risk of significant hyperbilirubinemia, but with a low positive predictive value (PPV) (18.9%). Of the 453 neonates above the 95th percentile, 275 subsequently developed significant hyperbilirubinemia, with a high PPV (60.7%), but with low sensitivity (28.3%). The 75th percentile was highly specific (81.9%) and moderately sensitive (79.8%). The area under the curve (AUC) for the TcB nomogram was 0.875.

[☆] Please cite this article as: Yu Z, Han S, Wu J, Li M, Wang H, Wang J, et al. Validation of transcutaneous bilirubin nomogram for identifying neonatal hyperbilirubinemia in healthy Chinese term and late-preterm infants: a multicenter study. J Pediatr (Rio J). 2014;90:273–8.

* Corresponding author.

E-mail: chen6010@163.com (C. Chen).

PALAVRAS-CHAVE

Hiperbilirrubinemia;
Icterícia;
Neonatal;
Bilirrubina;
Neonatos

Conclusions: this study validated the previously developed TcB nomogram, which could be used to predict subsequent significant hyperbilirubinemia in healthy Chinese term and late-preterm infants. However, combining TcB nomogram and clinical risk factors could improve the predictive accuracy for severe hyperbilirubinemia, which was not assessed in the study. Further studies are necessary to confirm this combination.

© 2014 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda.

Este é um artigo Open Access sob a licença de [CC BY-NC-ND](#)

Validação de um nomograma de bilirrubina transcutânea para identificação de hiperbilirrubinemia neonatal em neonatos a termo e pré-termo tardios saudáveis na China: um estudo multicêntrico

Resumo

Objetivo: validar de forma prospectiva um nomograma de bilirrubina transcutânea (BTc) para identificar hiperbilirrubinemia grave em neonatos a termo e pré-termo tardios saudáveis na China.

Métodos: foi realizado um estudo multicêntrico que incluiu 9174 neonatos a termo e pré-termo tardios saudáveis em oito unidades da China. Foram realizadas dosagens de BTc utilizando um bilirrubinômetro. Os valores de BTc foram traçados em um nomograma de BTc para identificar a capacidade de predição de hiperbilirrubinemia significativa.

Resultados: 972 recém-nascidos (10,6%) desenvolveram hiperbilirrubinemia significativa. O percentil 40 de nosso nomograma pode identificar todos os recém-nascidos com risco de hiperbilirrubinemia significativa, porém com baixo valor preditivo positivo (VPP) (18,9%). De 453 recém-nascidos acima do percentil 95, 275 recém-nascidos desenvolveram posteriormente hiperbilirrubinemia significativa, com VPP elevado (60,7%), porém com baixa sensibilidade (28,3%). O percentil de 75 foi altamente específico (81,9%) e moderadamente sensível (79,8%). A área sob a curva (ASC) de nosso nomograma de BTc foi de 0,875.

Conclusões: este estudo validou o nomograma de BTc, que pode ser utilizado para prever hiperbilirrubinemia significativa em neonatos a termo e pré-termo tardios saudáveis na China. Contudo, combinar o nomograma de BTc e fatores de risco clínicos pode melhorar a precisão de predição da hiperbilirrubinemia grave, o que não foi avaliado neste estudo. São necessários estudos adicionais para confirmar essa combinação.

© 2014 Sociedade Brasileira de Pediatria. Publicado por Elsevier Editora Ltda.

Este é um artigo Open Access sob a licença de [CC BY-NC-ND](#)

Introduction

Hyperbilirubinemia causes severe damage in term and late-preterm infants; the American Academy of Pediatrics (AAP) has formulated methods of surveillance, prediction, and therapy.¹ In China, bilirubin encephalopathy continues to occur, and 348 cases were reported from 28 hospitals from January to December of 2009.² Therefore, the identification of neonates at risk of developing significant hyperbilirubinemia and prevention of bilirubin encephalopathy remain a high priority among public health institutions.

The total serum bilirubin (TSB) level after birth was plotted on an hour-specific nomogram by Bhutani et al., and is a valuable method for assessing the risk of subsequent severe hyperbilirubinemia.³ The AAP has recommended the measurement of TSB in a predischarge newborn population for identification of severe hyperbilirubinemia, based on the Bhutani's nomogram.¹ However, measurements of TSB levels remain an invasive, stressful, and time-consuming procedure. Transcutaneous bilirubin (TcB) is less time-consuming, and can be used to screen for the need for blood sampling for serum bilirubin level, and thus reduce the measurements of TSB.⁴ The values of TcB after birth have also been plotted on an hour-specific TcB nomogram to predict severe hyperbilirubinemia in term and late-preterm

infants.⁵ These hour-specific TcB nomograms assessed pre-test predictive ability using retrospective data from the same developed TcB nomogram.⁶ Theoretically, a predictive nomogram should be developed in one sample and validated in another, and some studies prospectively assessed the post-test predictivity of TcB nomograms in different samples.^{7,8} The after-effect evaluation of the constructed TcB nomogram is very important to explore the possibility for future clinical application.

In 2010, the authors developed an hour-specific TcB nomogram based on TcB levels for the first 168 h after birth in 6,035 healthy term and late-preterm infants.⁹ Subsequently, they have conducted a multicenter study to verify the predictive value of the constructed TcB nomogram to identify severe hyperbilirubinemia in healthy term and late-preterm infants.

Methods**Setting**

Eight hospitals, including two general hospitals and six maternity hospitals, participated in the study. They were selected because they are the main tertiary centers in

their areas and because they agreed to participate in this study. The Ethics Committee of the Nanjing Maternity and Child Healthcare Hospital of the Nanjing Medical University approved the study and it was adopted by each participating center. The Nanjing Maternity and Child Healthcare Hospital of the Nanjing Medical University performed the statistical analysis of the collaborative data. The Children's Hospital of Fudan University did not participate in this survey, but served as a coordinating center and supervised the study.

Selection of participants

This multicenter prospective study was conducted between August 1, 2010, and December 31, 2011. Neonates with gestational age (GA) \geq 35 weeks and birth weight \geq 2,000 g were included, and all sick neonates who were admitted to the intensive care unit and those who required phototherapy before discharge were excluded. The decision to use phototherapy was made by the attending physicians according to AAP guidelines.¹ No prophylactic intervention for hyperbilirubinemia was used.

Measurements of TcB and TSB

TcB measurements were performed with a transcutaneous jaundice meter model JM-103 (Minolta - Osaka, Japan). A single device was used for all measurements in each participating unit. All measurements were performed by trained physicians according to the instructions of the manufacturer and using the standard technique.¹⁰ The physicians obtained TcB measurements, which were performed at two sites (the forehead and mid-sternum), and the mean of both measurements was calculated. According to previous studies, the JM-103 is less accurate at TcB levels $>$ 222 $\mu\text{mol/L}$, which were confirmed with a TSB measurement.¹⁰ The blood samples (50 μL) were drawn by heel stick, and special care was taken to avoid exposure of the collected samples to light. TSB assessment was performed in the clinical chemistry laboratory of each participating unit. Skilled physicians performed the TSB measurements using a UNI-STAT reflectance bilirubinometer (Reichert-Jung - Buffalo, NY, USA), according to the manufacturer's instructions. Significant hyperbilirubinemia was defined as TSB above the 95th percentile for age (high-risk zone), according to the hour-specific percentile nomogram presented by the AAP guidelines.¹

Follow-up of studied neonates

In each participating unit, the physicians obtained TcB measurements between 7:30 a.m. and 8:00 p.m., and then at time intervals of 12 ± 2 h. At least six measurements were obtained for each infant. A follow-up evaluation within 24 h to 96 h after discharge was offered to all neonates, depending on TcB levels before discharge, which were described in the authors' previous study.⁹ All perinatal and postpartum data of neonates were recorded in a single database for each unit during the study period. Each participating unit adopted the same clinical protocol study, method for sample collection, patient recruitment, and measurements

Table 1 Number of neonates from each hospital participating in the study.

Collaborative units	Participants, n
Nanjing Maternity and Child Healthcare Hospital, Nanjing Medical University	1,796
Inner Mongolia Maternal and Child Healthcare Hospital	1,703
The First Affiliated Hospital of Xinjiang Medical University	1,394
Changzhou Maternal and Child Healthcare Hospital	1,271
Gynecology and Obstetrics Hospital, Fudan University	1,046
The Fifth People's Hospital of Shenzhen	927
Guangxi Maternal and Child Health Hospital	565
Guangdong Maternal and Children's Hospital, Guangzhou Medical College	472
Total	9,174

of TcB and TSB. The coordinating center trained the investigators and supervised the implementation, so that the data from each unit could be pooled.

Statistical analysis

Data collected in the eight participating units were pooled by the Nanjing Maternity and Child Healthcare Hospital of the Nanjing Medical University, which conducted the statistical analysis. These data were entered into a custom-designed spreadsheet (Microsoft Excel 2003, Microsoft Corporation - Redmond, WA, USA) and checked for completeness, consistency, and accuracy by two researchers (Qing Sun and Xiaoyue Dong). After checking and verifying these data, the TcB values were plotted on the previously constructed TcB nomogram, separately by two researchers (Qing Sun and Xiaofan Sun).⁹ The sensitivity, specificity, positive predictive values (PPV), negative predictive values (NPV), and positive likelihood ratio (PLR) were calculated for the 40th, 75th, and 95th percentile of the TcB nomogram. Receiver operating characteristic (ROC) curve analysis was performed with the Statistical Package for Social Sciences (SPSS), version 16.0 (SPSS Inc. - Chicago, IL, USA), which was used to assess the predictive ability of the TcB nomogram.

Results

Eight hospitals participated in the multicenter study. The number of neonates from each hospital are listed in Table 1; 9,174 neonates (5,385 males and 3,789 females), of whom 945 (10.3%) were late-preterm, were enrolled in the study. Mean GA was 38.6 ± 2.9 weeks and mean birth weight was $2,875 \pm 412$ g; 5,275 (57.5%) neonates were born by cesarean section. Regarding feeding, 3,165 (34.5%) neonates were exclusively breast-fed, and 3,376 (36.8%) were exclusively bottle-fed. Of the total population studied, 514 (5.6%) neonates were small for gestational age, 661 (7.2%) experienced a weight loss greater than 10%, and 147 (1.6%) were diagnosed as having ABO incompatibility.

Table 2 Predictive characteristics of percentile values of predischarge TcB for subsequent significant hyperbilirubinemia.

Predischarge TcB		Significant hyperbilirubinemia		Predictive characteristics			
Percentile	Number (9174)	Present (972)	Absent (8202)	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)
Above the 95 th percentile	453	275	178	28.3	97.8	60.7	92.0
Below the 95 th percentile	8,721	697	8,024				
Above the 75 th percentile	2,258	776	1,482	79.8	81.9	34.4	97.2
Below the 75 th percentile	6,916	196	6,720				
Above the 40 th percentile	5,137	972	4,165	100.0	49.2	18.9	100.0
Below the 40 th percentile	4,037	0	4,037				

NPV, negative predictive value; PPV, positive predictive value; TcB, transcutaneous bilirubin.




Figure 1 ROC curve for predicting significant hyperbilirubinemia using the predischarge hour-specific TcB nomogram. ROC, receiver operating characteristic curve; TcB, transcutaneous bilirubin.

Regarding the percentiles, 972/9,174 (10.6%) neonates were above the 95th percentile based on AAP guidelines (significant hyperbilirubinemia). In 453 (4.9%) neonates, predischarge TcB was > 95th percentile (Table 2). Of these, 275 neonates subsequently developed significant hyperbilirubinemia (PPV: 60.7%, sensitivity: 28.3%). In 4,037 (36.8%) neonates, predischarge TcB was < 40th percentile; none of whom developed significant hyperbilirubinemia (NPV: 100.0% and specificity: 49.2%). The 75th percentile curve showed a sensitivity of 79.8% and an NPV of 97.2%; the specificity was 81.9%. The AUC for predischarge TcB percentiles was 0.875 (Figure 1).

The PLR that determines the risk assessment for subsequent significant hyperbilirubinemia for each risk zone is presented in Table 3. Among 453 neonates with predischarge TcB in the high-risk zone (> 95th percentile), 275 (60.7%) subsequently developed significant hyperbilirubinemia. Conversely, 178 newborns in the 95th percentile did not develop significant hyperbilirubinemia (PLR = 12.9) (Table 3). Of the 1,805 newborns in the upper-intermediate

risk zone (76th to 95th percentile), 501 (27.8%) jumped to the high-risk zone (PLR = 4.4). Of the 2,879 neonates in the lower-intermediate risk zone (40th to 75th percentile), 196 (6.8%) climbed to the high-risk zone (PLR = 2.0). Of the 4,037 neonates in the low-risk zone (< 40th percentile), none moved upwards into the high-risk zone (Table 3).

Discussion

TSB measurements are an invasive procedure that involves pain, neonatal stress, and risk of infection. A noninvasive determination of bilirubin concentrations (TcB) is advantageous, and is suitable for universal neonatal screening.¹¹ The new generation of noninvasive TcB-measuring devices (BiliCheckTM and JM-103) have presented good correlations with TSB measurements (BiliCheckTM: 0.8212, JM-103: 0.8686).¹² Recently, some studies developed predictive nomograms based on measurements of TcB or TSB to assess the risk for significant hyperbilirubinemia in healthy term and late-preterm infants.^{13–18} The results showed that the TcB nomogram was equivalent to the TSB nomogram, and both could be used to identify subsequent significant hyperbilirubinemia.

A predictive nomogram should be developed in one sample and validated in another. The present study was a multicenter study to verify the predictive value of the TcB nomogram constructed in 2010.⁹ The result showed that the AUC was 0.875, which was lower than the pre-test predictive ability in the previous study (AUC = 0.920). The previously constructed TcB nomogram was developed from a single hospital, which could not represent the demographic characteristics of the Chinese neonatal population. The multicenter study included eight units, which showed different genetic and environmental features. Therefore, a population-based TcB nomogram should be constructed, which should show a better predictive ability.

The rate of TcB increase is affected by smaller gestational age, blood incompatibilities, glucose-6-phosphate dehydrogenase deficiency, increased weight loss, and exclusive breastfeeding.¹⁹ Therefore, risk factors should be assessed when planning appropriate follow-up strategies according to the predischarge TcB.²⁰ Six centers assessed the predictive value of predischarge TcB, and the AUC was 0.86; however, combined clinical risk factors (earlier GA, bruising, positive direct antiglobulin test, Asian race, exclu-

Table 3 Predictive ability of percentile values of predischage TcB for subsequent significant hyperbilirubinemia.

Risk zone	Predischage TcB		Significant hyperbilirubinemia		Predictive ability	
	Percentile	Number (9,174)	Present (972)	Absent (8,202)	Probability of disease	PLR
High-risk	> 95 th	453	275	178	60.7%	12.9
Upper-intermediate	76 th -95 th	1,805	501	1,304	27.8%	4.4
Lower-intermediate	40 th -75 th	2,879	196	2,683	6.8%	2.0
Low-risk	< 40 th	4,037	0	4,037	0.0%	0

PLR, positive likelihood ratio; TcB, transcutaneous bilirubin

sive breastfeeding, blood type incompatibility, and jaundice extent) was better (AUC = 0.95).²¹ Another study evaluated the predictive performance of predischage bilirubin risk zone (AUC = 0.88); however, combined clinical risk factors (GA, and percentage of weight loss per day on the first two days) showed better accuracy (AUC = 0.96).²² Thus, the risk factors for developing significant hyperbilirubinemia in the Chinese neonatal population should have been investigated in combination with a TcB nomogram, which could improve the predictive accuracy.

The study has some limitations. Firstly, the previous TcB nomogram was constructed from a single, tertiary-care center, which does not represent population-based study data. Secondly, the previous TcB nomogram did not combine the TcB nomogram with other clinical risk factors, such as GA and exclusive breastfeeding, which may improve the prediction of subsequent hyperbilirubinemia. Due to the relative limitations of previous TcB nomogram, the authors are currently conducting a multicenter study (ClinicalTrials.gov Identifier: NCT01763632), in which 17 hospitals in China will participate from January to December, 2013, to develop an hour-specific TcB nomogram. The constructed TcB nomogram, which will combine predischage TcB with other clinical risk factors, may better represent the Chinese neonatal population.

Conclusion

The multicenter study validated the TcB nomogram, which is a useful tool for predicting subsequent severe hyperbilirubinemia in Chinese healthy term and late-preterm infants. However, the study did not combine predischage TcB with clinical risk factors (such as GA, exclusive breastfeeding, cephalhematoma, significant bruising, or previous sibling with jaundice) to determine the risk for healthy term and late-preterm infants developing subsequent severe hyperbilirubinemia. Further studies are necessary to confirm this combination.

Funding

This work was supported by grants from the Key Medical Personnel Foundation of Jiangsu Province (Grant No. RC2011021), the Nanjing Medical Science and Technique Development Foundation (QRX11107), and the Nanjing Municipal Medical Science Development Foundation, Nanjing, Jiangsu, China (ZKX12044).

Conflicts of interest

The authors declare no conflicts of interest.

Acknowledgements

The authors are grateful to the staff of the Affiliation for their support and comments during the preparation of this manuscript. The authors would like to thank the following investigators who participated in the multicenter study: Jin Wang (Department of Neonatology, Children's Hospital of Fudan University, Shanghai, China), Qing Sun (Department of Pediatrics, Nanjing Maternity and Child Health Care Hospital of Nanjing Medical University, Nanjing, China), Xiaoyue Dong (Department of Pediatrics, Nanjing Maternity and Child Health Care Hospital of Nanjing Medical University, Nanjing, China), Xiaofan Sun (Department of Pediatrics, Nanjing Maternity and Child Health Care Hospital of Nanjing Medical University, Nanjing, China), Hongyun Wang (Department of Neonatology, Inner Mongolia Maternal and Child Health Care Hospital, Hohhot, China), Yanping Zhu (Department of Neonatology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China), Ying Wang (Department of Neonatology, Changzhou Maternal and Child Health Care Hospital, Changzhou, China), Xiaolei Zhuang (Department of Neonatology, Gynecology and Obstetrics Hospital, Fudan University, Shanghai, China), Jun Long (Department of Pediatrics, The Fifth People's Hospital of Shenzhen, Shenzhen, China), and Qiufen Wei (Department of Neonatology, Guangxi Maternal and Child Health Hospital, Nanning, China).

References

1. American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. *Pediatrics*. 2004;114:297-316.
2. Subspecialty Group of Neonatology, Society of Pediatrics, Chinese Medical Association; Chinese Multicenter Study Coordination Group for Neonatal Bilirubin Encephalopathy. Clinical characteristics of bilirubin encephalopathy in Chinese newborn infants-a national multicenter survey. *Zhonghua Er Ke Za Zhi*. 2012;50:331-5.
3. Bhutani VK, Johnson L, Sivieri EM. Predictive ability of a predischage hour-specific serum bilirubin for subsequent significant hyperbilirubinemia in healthy term and near-term newborns. *Pediatrics*. 1999;103:6-14.

4. Mishra S, Chawla D, Agarwal R, Deorari AK, Paul VK, Bhutani VK. Transcutaneous bilirubinometry reduces the need for blood sampling in neonates with visible jaundice. *Acta Paediatr.* 2009;98:1916–9.
5. Dalal SS, Mishra S, Agarwal R, Deorari AK, Paul V. Does measuring the changes in TcB value offer better prediction of Hyperbilirubinemia in healthy neonates? *Pediatrics.* 2009;124:e851–7.
6. Mishra S, Chawla D, Agarwal R, Deorari AK, Paul VK. Transcutaneous bilirubin levels in healthy term and late preterm Indian neonates. *Indian J Pediatr.* 2010;77:45–50.
7. De Luca D, Romagnoli C, Tiberi E, Zuppa AA, Zecca E. Skin bilirubin nomogram for the first 96 h of life in a European normal healthy newborn population, obtained with multiwave length transcutaneous bilirubinometry. *Acta Paediatr.* 2008;97:146–50.
8. Maisels MJ, Kring E. Transcutaneous bilirubin levels in the first 96 hours in a normal newborn population of > or = 35 weeks' gestation. *Pediatrics.* 2006;117:1169–73.
9. Yu ZB, Dong XY, Han SP, Chen YL, Qiu YF, Sha L, et al. Transcutaneous bilirubin nomogram for predicting neonatal hyperbilirubinemia in healthy term and late-preterm Chinese infants. *Eur J Pediatr.* 2011;170:185–91.
10. Ho HT, Ng TK, Tsui KC, Lo YC. Evaluation of a new transcutaneous bilirubinometer in Chinese newborns. *Arch Dis Child Fetal Neonatal Ed.* 2006;91:F434–8.
11. Wainer S, Rabi Y, Parmar SM, Allegro D, Lyon M. Impact of skin tone on the performance of a transcutaneous jaundice meter. *Acta Paediatr.* 2009;98:1909–15.
12. Romagnoli C, Tiberi E, Barone G, Curtis MD, Regoli D, Paolillo P, et al. Development and validation of serum bilirubin nomogram to predict the absence of risk for severe hyperbilirubinaemia before discharge: a prospective, multicenter study. *Ital J Pediatr.* 2012;38:6.
13. Bental YA, Shiff Y, Dorsht N, Litig E, Tuval L, Mimouni FB. Bhutani-based nomograms for the prediction of significant hyperbilirubinaemia using transcutaneous measurements of bilirubin. *Acta Paediatr.* 2009;98:1902–8.
14. Kaur S, Chawla D, Pathak U, Jain S. PredischARGE non-invasive risk assessment for prediction of significant hyperbilirubinemia in term and late preterm neonates. *J Perinatol.* 2012;32:716–21.
15. Romagnoli C, Tiberi E, Barone G, De Curtis M, Regoli D, Paolillo P, et al. Validation of transcutaneous bilirubin nomogram in identifying neonates not at risk of hyperbilirubinaemia: a prospective, observational, multicenter study. *Early Hum Dev.* 2012;88:51–5.
16. Sarici SU, Serdar MA, Korkmaz A, Erdem G, Oran O, Tekinalp G, et al. Incidence, course, and prediction of hyperbilirubinemia in near-term and term newborns. *Pediatrics.* 2004;113:775–80.
17. Keren R, Bhutani VK, Luan X, Nihtianova S, Cnaan A, Schwartz JS. Identifying newborns at risk of significant hyperbilirubinaemia: a comparison of two recommended approaches. *Arch Dis Child.* 2005;90:415–21.
18. Newman TB, Liljestrand P, Escobar GJ. Combining clinical risk factors with serum bilirubin levels to predict hyperbilirubinemia in newborns. *Arch Pediatr Adolesc Med.* 2005;159:113–9.
19. Mantagou L, Fouzas S, Skylogianni E, Giannakopoulos I, Karatza A, Varvarigou A. Trends of transcutaneous bilirubin in neonates who develop significant hyperbilirubinemia. *Pediatrics.* 2012;130:e898–904.
20. Maisels MJ. Risk assessment and follow-up are the keys to preventing severe hyperbilirubinemia. *J Pediatr (Rio J).* 2011;87:275–6.
21. Bhutani VK, Stark AR, Lazzaroni LC, Poland R, Gourley GR, Kazmierczak S, et al. PredischARGE screening for severe neonatal hyperbilirubinemia identifies infants who need phototherapy. *J Pediatr.* 2013;162, 477-82.e1.
22. Keren R, Luan X, Friedman S, Saddlemire S, Cnaan A, Bhutani VK. A comparison of alternative risk-assessment strategies for predicting significant neonatal hyperbilirubinemia in term and near-term infants. *Pediatrics.* 2008;121:e170–9.